{
    "nct_id": "NCT05571293",
    "official_title": "Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients",
    "inclusion_criteria": "* 18 years of age or older\n* Histologically, cytologically, or clinically confirmed adenocarcinoma of the colon or rectal cancer as long as there is no plans for neoadjuvant radiation for the patients with rectal cancer. Note: patients can enroll in cohort B while awaiting mismatch repair testing results. If noted to be dMMR/MSI-High, they would be still considered evaluable and moved to cohort C.\n* If capable of becoming pregnant, or getting someone else pregnant, must be willing to use highly effective contraception from Screening period through 90 days following the last dose of study drug\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic cancer (cancer that has spread to other parts of the body)\n* Previous treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1 or PD-L1\n* Currently participating in another study and receiving a study drug\n* History of severe allergic reactions to immunotherapies\n* Pregnant or breastfeeding\n* Active infection requiring treatment\n* On immunosuppressive medications\n* Active cardiovascular disease, such as stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure, or serious uncontrolled cardiac arrhythmia requiring medication that may prevent surgery\n\nParticipants in Cohort C must be dMMR/MSI-High.",
    "miscellaneous_criteria": ""
}